CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
暂无分享,去创建一个
R. Gascoyne | M. Ziepert | N. Schmitz | D. Scott | L. Sehn | J. Connors | K. Savage | M. Pfreundschuh | M. Loeffler | S. Zeynalova | M. Nickelsen | B. Glass | D. Villa | R. Kansara
[1] R. Gascoyne,et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. , 2016, Blood.
[2] S. Mourah,et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. , 2015, Blood.
[3] M. Di Nicola,et al. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Bøgsted,et al. Validation of the German high-grade non-hodkin lymphoma study group (DSHNHL) prognostic model for CNS replapse in a large cohort of PET/CT staged patients , 2015, ICML 2015.
[5] K. Hoang-Xuan,et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma , 2015, Neurology.
[6] Michael Hallek,et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Scott E. Smith,et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.
[8] M. Pfreundschuh,et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Opat,et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma , 2014, British Journal of Cancer.
[10] W. Wilson,et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma , 2014, Haematologica.
[11] C. Fletcher,et al. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era , 2014, Leukemia & lymphoma.
[12] J. Delabie,et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E. Thiel,et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas , 2013, Haematologica.
[14] A. Rosenwald,et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). , 2012, The Lancet. Oncology.
[15] V. Pavone,et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. , 2012, Blood.
[16] M Ladetto,et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Imrie,et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literature , 2012, British journal of haematology.
[19] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Gordon,et al. Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era , 2012, Cancer.
[21] W. Wilson,et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype , 2012, Haematologica.
[22] N. Schmitz,et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] G. Schulte-Altedorneburg,et al. Current strategies in the diagnosis of diffuse large B‐cell lymphoma of the central nervous system , 2012, British journal of haematology.
[24] R. Kridel,et al. Prevention of CNS relapse in diffuse large B-cell lymphoma. , 2011, The Lancet. Oncology.
[25] T. Molina,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.
[26] N. Schmitz,et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. López-Guillermo,et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Gascoyne,et al. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse , 2011, Haematologica.
[29] X. Hou,et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab , 2011, Annals of Hematology.
[30] M. Ziepert,et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] P. Hammerman,et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.
[32] R. Gascoyne,et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] N. Schmitz,et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.
[34] J. Briones,et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[36] F. Feuerhake,et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.
[37] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[38] N. Schmitz,et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[40] S. Kvaløy,et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] P. Mclaughlin,et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.
[42] D. Collett. Modelling Survival Data in Medical Research , 1994 .
[43] M. Oken,et al. CENTRAL NERVOUS SYSTEM RELAPSE IN UNFAVOURABLE-HISTOLOGY NON-HODGKIN'S LYMPHOMA: IS PROPHYLAXIS INDICATED? , 1984, The Lancet.
[44] L. Sehn,et al. Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of central nervous system relapse with R-CHOP(-like) therapy , 2015, ICML 2015.
[45] J. Friedberg,et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] A. Horwich,et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] T. Molina,et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.